Abstract：Objective: To evaluate the incidence of hepatocellular carcinoma(HCC) and to identify the risk factors of HCC in patients with Budd-Chiari syndrome(BCS). Methods: Between July 1988 and May 2018, 224 consecutive Chinese patients with BCS were treated in our center. One hundred and ninety-nine patients without other risk factors of HCC were involved in our study. Continuous variables were expressed as average values and standard deviations. Categorical variables were summarized as absolute numbers and frequencies. Cumulative incidence of HCC was assessed by Kaplan-Meier curves and compared by log-rank test. Independent predictors of HCC were calculated with the Cox regression model. Results: Interventional therapy was successfully implemented in 166 of the 199 patients, and 32 patients were treated by anticoagulation therapy and symptomatic treatment. Two patients who died 16 h and 48 h after operation(disseminated intravenous coagulation and multiple systemic organ failure, respectively) and seventeen patients lost to follow-up were excluded. The remaining 180 patients were eligible for data analysis. Eleven patients suffered from HCC during follow-up, indicating the incidence was 6.1%. The cumulative 5-, 10-, 20-, 30- incidence of HCC were 0.6%, 4.2%, 7.0%, 18.4%, respectively. In our multivariate Cox regression and analysis, restenosis of hepatic vein or inferior vena cava after interventional treatment was the only significant factor associated with the development of HCC in patients with BCS(P<0.05). The cumulative incidence of HCC was significantly higher in the restenosis group than the other(P<0.05). Conclusion: In patients with BCS, HCC is a long-term complication. Furthermore, restenosis of hepatic venous outflow tract is the only significant factor associated with the development of HCC. Therefore, long-term follow-up should be emphasized to achieve timely diagnosis of early stage HCC and treatment of restenosis.
王巧争，徐 克. 布加综合征并发肝癌的危险因素分析[J]. 中国临床医学影像杂志, 2020, 31(2): 102-105.
WANG Qiao-zheng, XU Ke. Risk factors of hepatocellular carcinoma in patients with Budd-Chiari syndrome. JOURNAL OF CHINA MEDICAL IMAGING, 2020, 31(2): 102-105.
[1]European Association for the Study of the Liver. Electronic Address. EASL Clinical Practice Guidelines: Vascular diseases of the liver[J]. J Hepatol, 2016, 64(1): 179-202.
[2]Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies[J]. Hepatology, 2003, 38(4): 793-803.
[3]Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion[J]. Hepatology, 1998, 28(5): 1191-1198.
[4]European Association for the Study of Liver, European Organisation For and C Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943.
[5]Paul SB, Chalamalasetty SB, Vishnubhatla S, et al. Clinical profile, etiology and therapeutic outcome in 324 hepatocellular carcinoma patients at a tertiary care center in India[J]. Oncology, 2009, 77(3-4): 162-171.
[6]Velazquez RF, Rodriguez M, Navascues CA, et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis[J]. Hepatology, 2003, 37(3): 520-527.
[7]Rowe IA, Tripathi D. Editorial: TIPSS in patients with cirrhosis and hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2015, 41(2): 230.
[8]Bettinger D, Knuppel E, Euringer W, et al. Efficacy and safety of transjugular intrahepatic portosystemic shunt(TIPSS) in 40 patients with hepatocellular carcinoma[J]. Aliment Pharmacol Ther, 2015, 41(1): 126-136.
[9]Matsui S, Ichida T, Watanabe M, et al. Clinical features and etiology of hepatocellular carcinoma arising in patients with membranous obstruction of the inferior vena cava: in reference to hepatitis viral infection[J]. J Gastroenterol Hepatol, 2000, 15(10): 1205-1211.
[10]Gwon D 2nd, Ko GY, Yoon HK, et al. Hepatocellular carcinoma associated with membranous obstruction of the inferior vena cava: incidence, characteristics, and risk factors and clinical efficacy of TACE[J]. Radiology, 2010, 254(2): 617-626.
[11]Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors[J]. Gut, 2008, 57(6): 828-835.
[12]Eapen CE, Mammen T, Moses V, et al. Changing profile of Budd Chiari syndrome in India[J]. Indian J Gastroenterol, 2007, 26(2): 77-81.
[13]Kew MC, Mcknight A, Hodkinson J, et al. The role of membranous obstruction of the inferior vena cava in the etiology of hepatocellular carcinoma in Southern African blacks[J]. Hepatology, 1989, 9(1): 121-125.
[14]Rector WG Jr, Xu YH, Goldstein L, et al. Membranous obstruction of the inferior vena cava in the United States[J]. Medicine(Baltimore), 1985, 64(2): 134-143.
[15] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范（2017年版）[J]. 消化肿瘤杂志：电子版，2017，9（4）：213-228.
[16]Ren W, Qi X, Yang Z, et al. Prevalence and risk factors of hepatocellular carcinoma in Budd-Chiari syndrome: a systematic review[J]. Eur J Gastroenterol Hepatol, 2013, 25(7): 830-841.
[17]Park H, Yoon JY, Park KH, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: a single center experience with long-term follow-up in South Korea[J]. World J Gastroenterol, 2012, 18(16): 1946-1952.
[18]Sakr M, Abdelhakam SM, Dabbous H, et al. Characteristics of hepatocellular carcinoma in Egyptian patients with primary Budd-Chiari syndrome[J]. Liver Int, 2017, 37(3): 415-422.
[19]Paul SB, Shalimar, Sreenivas V, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction[J]. Aliment Pharmacol Ther, 2015, 41(10): 961-971.
[20]Bayraktar UD, Seren S, Bayraktar Y. Hepatic venous outflow obstruction: three similar syndromes[J]. World J Gastroenterol, 2007, 13(13): 1912-1927.
2020, Vol. 31 
